S&P Futures
4,134.75 -13.00 (-0.31%) Dow Futures
33,889.00 -73.00 (-0.21%) Nasdaq Futures
12,575.00 -49.00 (-0.39%) Russell 2000 Futures
1,985.80 -7.70 (-0.39%) Crude Oil
73.56 +0.17 (+0.23%) Gold
1,886.40 +9.80 (+0.52%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 139.43 |
| Open | 138.51 |
| Bid | 137.09 x 800 |
| Ask | 138.27 x 1200 |
| Day's Range | 137.52 - 139.69 |
| 52 Week Range | 105.43 - 183.00 |
| Volume | |
| Avg. Volume | 938,859 |
| Market Cap | 25.622B |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.78 |
| Earnings Date | Feb 15, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 162.57 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SGEN
Related Research
- Seagen Inc.Analyst Report: Seagen Inc.Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.RatingFair ValueEconomic Moat2 months agoMorningstar
- Business Wire
Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
BOTHELL, Wash., January 19, 2023--Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TUKYSA® (tucatinib) in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. TUKYSA is approved under the FDA’s Accelerated Approval Program based on tum
- Business Wire
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
BOTHELL, Wash., January 19, 2023--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update.
- Simply Wall St.
We're Not Worried About Seagen's (NASDAQ:SGEN) Cash Burn
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
